Structured Abstract
Background The existence of few biomarkers and the lack of a better understanding of the pathophysiology of levodopa-induced dyskinesia (LID) in Parkinson’s disease (PD) require new approaches, as the metabolomic analysis, for discoveries.
Objectives We aimed to identify a metabolic profile associated with LID in patients with PD in an original cohort, and to confirm the results in an external cohort (BioFIND).
Methods In the original cohort, plasma and CSF were collected from 20 healthy controls, 23 patients with PD without LID, and 24 patients with PD with LID. LC-MS/MS and metabolomics data analysis were used to perform untargeted metabolomics. Untargeted metabolomics data from the BioFIND cohort were analyzed.
Results We identified a metabolic profile associated with LID in PD, composed of multiple metabolic pathways. In particular, the dysregulation of glycosphingolipids metabolic pathway was more related to LID and was strongly associated with the severity of dyskinetic movements. Further, bile acid biosynthesis and C21-steroid hormone biosynthesis metabolites simultaneously found in plasma and CSF have distinguished patients with LID from other participants. Levels of cortisol and cortisone were reduced in patients with PD and LID compared to patients with PD without LID. Data from the BioFIND cohort confirmed dysregulation in plasma metabolites from the bile acid biosynthesis and C21-steroid hormone biosynthesis pathways.
Conclusion There is a distinct metabolic profile associated with LID in PD, both in plasma and CSF, which may be associated with the dysregulation of lipid metabolism and neuroinflammation.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study was supported by the Fundação de Amparo a Pesquisa do Estado de São Paulo (FAPESP; 159688/2015-9 and 2014/07125-6) and Conselho Nacional de Desenvolvimento Cientifico e Tecnologico (CNPq; 2012/17626-7). The BioFIND study funding was provided by The Michael J. Fox Foundation for Parkinson&s Research and National Institute of Neurological Disorders and Stroke.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ribeirão Preto Medical School Ethics Committee (Number 3.036.243)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
Financial Disclosure: Dr. TUMAS received honoraria from Teva Brasil, UCB Biopharma and Ipsen, and travel support for medical conferences from Roche.
Funding Sources for the Study: This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP; 159688/2015-9 and 2014/07125-6) and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq; 2012/17626-7). The BioFIND study funding was provided by The Michael J. Fox Foundation for Parkinson’s Research and National Institute of Neurological Disorders and Stroke.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
